Manish Baviskar, Hubot CDMO, explains which AI skills validation engineers need first and why AI model updates must go through GMP change control.
|Articles|May 13, 2014
The IMA Group at Interpack 2014
The IMA Group at Interpack 2014: innovation, awareness, ability Welcoming you to Hall 17 The IMA stand at Interpack 2014 will be very innovative: a chance to discover what?s new in the IMA world. The high precision technology of IMA?s machines and complete lines will be revealed in the tiniest detail through jumbo screen videowalls. Company name:? IMA S.p.A. Websites: www.ima.it ??www.ima-pharma.com E-mail: visit the IMA website, Contacts section Name of product: The IMA Group at Interpack 2014
Advertisement
The IMA Group at Interpack 2014:
innovation, awareness, ability- Welcoming you toHall 17
The
IMA stand
at
Interpack 2014
will be very innovative: a chance to discover
what’s new in the IMA world.
The high precision technology of IMA’s machines and complete lines will be revealed in the tiniest detail through jumbo screen videowalls.
Company name: IMA S.p.A.
Websites:
E-mail: visit the IMA website, Contacts section
Name of product: The IMA Group at Interpack 2014
Advertisement
Related to this article
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
Aleksandra Zuraw, senior veterinary pathologist at Charles River, discusses how chain of custody, good laboratory practice, quality control, and validation are applied to digital pathology data used in drug development.
Ron Filler, Drug Development Consultants, explains how USP's 1074 revision brings human-relevant safety science to formulators and excipient makers.
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF in Tarrytown, spoke with PharmTech at AAPS PharmSci 360 about formulation and characterization challenges for amorphous solid dispersions.
FDA draft guidance on individualized genome editing lets BLAs add patient-specific variants without new trials, shifting evidence to CMC assay data.
Bill Williams, AAPS, compares KinetiSol and spray drying for amorphous solid dispersions, covering 75% drug loading, pill burden, weakly basic drug release, and process limits.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
From URS to Acceptance Evidence: Defining and Testing Interfaces in Pen Injector Assembly
2
AAPS PharmSci 360 2026: IND-Enabling Studies vs Animal Data
3
PharmTech Weekly Roundup—October 23, 2026: CMC Considerations, Rare Disease Development, Standards Harmonization
4
Formulation Risk Needs One Accountable Owner: AAPS PharmSci 360 2026
5